Laura Padullés

508 total citations
17 papers, 311 citations indexed

About

Laura Padullés is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Laura Padullés has authored 17 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Laura Padullés's work include Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers), Nonmelanoma Skin Cancer Studies (5 papers) and Cutaneous Melanoma Detection and Management (5 papers). Laura Padullés is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (6 papers), Nonmelanoma Skin Cancer Studies (5 papers) and Cutaneous Melanoma Detection and Management (5 papers). Laura Padullés collaborates with scholars based in Spain, United States and Netherlands. Laura Padullés's co-authors include Anna Feliu, David Price, Thys van der Molen, Marc Miravitlles, H. Worth, Nina Godtfredsen, Nicolás Roche, Fernando De Benedetto, Claes‐Göran Löfdahl and Juan José Soler‐Cataluña and has published in prestigious journals such as SHILAP Revista de lepidopterología, CHEST Journal and British Journal of Cancer.

In The Last Decade

Laura Padullés

14 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Padullés Spain 7 258 172 37 19 19 17 311
Kwok Sang Yee China 7 230 0.9× 104 0.6× 30 0.8× 9 0.5× 6 0.3× 10 293
R.P. Bowler United States 7 180 0.7× 76 0.4× 45 1.2× 6 0.3× 5 0.3× 8 232
K. Viel Germany 10 336 1.3× 287 1.7× 28 0.8× 5 0.3× 10 0.5× 14 393
Jasmin Honkamäki Finland 6 119 0.5× 182 1.1× 19 0.5× 5 0.3× 4 0.2× 8 238
Chin-Chou Wang Taiwan 7 114 0.4× 67 0.4× 26 0.7× 6 0.3× 33 1.7× 7 198
Michael Larbig Switzerland 8 260 1.0× 246 1.4× 10 0.3× 2 0.1× 7 0.4× 18 336
Soma Datta United States 6 95 0.4× 123 0.7× 42 1.1× 9 0.5× 2 0.1× 9 288
Emily Farrington United Kingdom 4 245 0.9× 216 1.3× 4 0.1× 12 0.6× 11 0.6× 7 303
Emily Beck United States 7 97 0.4× 24 0.1× 35 0.9× 10 0.5× 8 0.4× 18 204
Jussi Haanpää Finland 5 242 0.9× 275 1.6× 11 0.3× 7 0.4× 3 0.2× 8 331

Countries citing papers authored by Laura Padullés

Since Specialization
Citations

This map shows the geographic impact of Laura Padullés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Padullés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Padullés more than expected).

Fields of papers citing papers by Laura Padullés

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Padullés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Padullés. The network helps show where Laura Padullés may publish in the future.

Co-authorship network of co-authors of Laura Padullés

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Padullés. A scholar is included among the top collaborators of Laura Padullés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Padullés. Laura Padullés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Bhatia, Neal, Edward Lain, Abel Jarell, et al.. (2024). Safety and tolerability of tirbanibulin ointment 1% treatment on 100 cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study. JAAD International. 17. 6–14. 5 indexed citations
2.
3.
Schlesinger, Todd, et al.. (2024). 52742 Real-world patient/clinician-reported outcomes of tirbanibulin for actinic keratosis: indirect comparison between KLIR and PROAK studies. Journal of the American Academy of Dermatology. 91(3). AB79–AB79.
4.
5.
Cutler, David L., et al.. (2022). Contact Sensitization and Phototoxic and Photoallergic Potential of Tirbanibulin 1% Ointment in Healthy Volunteers. SHILAP Revista de lepidopterología. 3(2). 100170–100170. 2 indexed citations
6.
Berman, Brian, et al.. (2022). Efficacy of tirbanibulin ointment 1% across different patient populations: pooled results from two Phase 3 studies. SKIN The Journal of Cutaneous Medicine. 6(2). s27–s27. 1 indexed citations
7.
Berman, Brian, Todd Schlesinger, Neal Bhatia, et al.. (2022). Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions. SKIN The Journal of Cutaneous Medicine. 6(2). s25–s25. 1 indexed citations
8.
Miravitlles, Marc, H. Worth, Juan José Soler‐Cataluña, et al.. (2016). The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS). COPD Journal of Chronic Obstructive Pulmonary Disease. 13(5). 561–568. 15 indexed citations
9.
Pascual-Guàrdia, Sergi, Anthony De Soyza, John Haughney, et al.. (2015). Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. npj Primary Care Respiratory Medicine. 25(1). 15018–15018. 29 indexed citations
10.
Miravitlles, Marc, H. Worth, Juan José Soler‐Cataluña, et al.. (2014). Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respiratory Research. 15(1). 122–122. 130 indexed citations
11.
Miravitlles, Marc, H. Worth, David Price, et al.. (2014). Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respiratory Research. 15(1). 122–122. 21 indexed citations
12.
Palen, Job van der, Paul van der Valk, Laura Padullés, et al.. (2013). Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opinion on Drug Delivery. 10(8). 1023–1031. 58 indexed citations
13.
Miravitlles, Marc, H. Worth, Juan José Soler‐Cataluña, et al.. (2013). P116 Observational study to characterise 24-hour COPD symptoms: cross-sectional results from the ASSESS study: Abstract P116 Table 1.. Thorax. 68(Suppl 3). A127.1–A127. 1 indexed citations
14.
Palen, Job van der, Paul van der Valk, Laura Padullés, et al.. (2012). Preference, satisfaction and critical errors with Genuair® and HandiHaler® in patients with COPD. 40. 2177. 5 indexed citations
15.
Palen, Job van der, Paul van der Valk, Laura Padullés, et al.. (2012). Comparison of the Preference, Satisfaction, and Critical Errors Made With Genuair® and HandiHaler® in patients with COPD. CHEST Journal. 142(4). 717A–717A. 2 indexed citations
16.
Mollevı́, David G., Àlvaro Aytés, Mireia Berdiel‐Acer, et al.. (2009). PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts. Molecular Cancer. 8(1). 46–46. 7 indexed citations
17.
Mollevı́, David G., Àlvaro Aytés, Laura Padullés, et al.. (2008). PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. British Journal of Cancer. 99(10). 1718–1725. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kwok Sang Yee Breakdown of academic impact, for papers by R.P. Bowler Breakdown of academic impact, for papers by K. Viel Breakdown of academic impact, for papers by Jasmin Honkamäki Breakdown of academic impact, for papers by Chin-Chou Wang Breakdown of academic impact, for papers by Michael Larbig Breakdown of academic impact, for papers by Soma Datta Breakdown of academic impact, for papers by Emily Farrington Breakdown of academic impact, for papers by Emily Beck Breakdown of academic impact, for papers by Jussi Haanpää
Rankless by CCL
2026